Sharechat Logo

Julie Tay appointed as independent director

Monday 1st May 2023

Text too small?

EBOS Group Limited (EBOS) is pleased to announce the appointment of Julie Tay as an independent director, effective 15 May 2023.


Ms Tay joins EBOS with over 30 years’ experience in international executive and non-executive roles across consumer healthcare, medical devices and digital healthcare.


Ms Tay is currently a director of Sonova Holdings, a global hearing care solutions company, headquartered in Switzerland and listed on the Swiss stock exchange.


During her executive career, Ms Tay was most recently Senior Vice President and Managing Director, Asia Pacific for Align Technology, which is a global medical device company focused on the orthodontic and dental markets. In this role she launched Align Technology in Asia and, over nine years, established the company’s primary product, Invisalign, as a leading brand across 14 markets. During this time, Ms Tay was also a member of the global Executive Management Committee for Align Technology.


Prior to this time, Ms Tay was regional head of Bayer Healthcare (Diabetes Care) in Asia Pacific and also previously held senior executive roles in Asia at Johnson Diversey and Johnson & Johnson.


Ms Tay holds a Bachelor of Psychology and Political Science from the National University of Singapore and an MBA from Curtin University of Technology in Perth. Ms Tay has also completed the International Directors Program at INSEAD.


EBOS Chair Liz Coutts said “Julie’s extensive experience in Asia within the healthcare sector will be invaluable to EBOS as we explore expansion opportunities in the region. We look forward to welcoming her to the Board.”


The Board has determined that Ms Tay will be an independent director (as defined in the NZX Listing Rules). Ms Tay resides in Singapore.


This appointment is consistent with EBOS’ Board succession planning previously announced. EBOS has appointed three new directors within the last two years with a diverse mix of skills. The Board now comprises eight directors, all of whom are independent.


For further information please contact:

Martin Krauskopf

Executive General Manager, Strategy and Mergers & Acquisitions

+61 3 9918 5555


Authorised for lodgement with NZX and ASX by Janelle Cain, General Counsel, EBOS Group Limited.


About EBOS Group


EBOS Group Limited NZBN 9429031998840 (NZX/ASX Code: EBO) is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading Australasian animal care brand owner, product marketer and distributor.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Me Today - Notice of Annual Shareholder Meeting
FSF - Director Scott St John to retire from Fonterra Board
Greenfern announces change in Chief Financial Officer
AIA Provision of Financial Assistance - Employee Share Plan
CBD - Recording and Presentation of Investor Call
CRP - Korella North Mining Lease Lodgement Approved
Genesis Energy launches new strategy
November 30th Morning Report
IFT270 - Interest Rate Reset